Arca
Skip to content
Tools
Tools

Cutaneous T-cell lymphoma

Drug research and approvals for cutaneous T-cell lymphoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 22, 2026, 60 studies of cutaneous T-cell lymphoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 3 drug trials for it since 2013, FDA has 7 approved and 18 open orphan designations naming it, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 60
  • Trials authorized in Canada: 3
  • FDA orphan approvals: 7
  • EU medicines: 2

Recruiting now

Newest posted first, of 60 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition or a subtype of it, from ChEMBL's drug indications

Approved 10

Phase 3 5

Phase 2 12 of 31

Phase 1 or earlier 12 of 48

How its trials ended

311 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 103 whose ending is known, 29% met their primary endpoint, 2% missed it and 69% stopped early.

  • Completed, result not reported12741%
  • Ongoing6320%
  • Stopped: other or unclear3210%
  • Met its primary endpoint3010%
  • Stopped: enrollment or feasibility237%
  • Status unknown186%
  • Stopped: sponsor or business decision83%
  • Stopped: funding41%
  • Missed its primary endpoint21%
  • Stopped: lack of efficacy21%
  • Stopped: safety21%

Trials authorized in Canada

Newest first; search them all in Canada trials
Nov 18, 2022An interventional, single-arm, open-label phase II study investigating the efficacy and safety of ANTI-PD1 immunotherapy for the treatment of patients with…Libtayo (cemiplimab)Alberta Health Services, Cross Cancer InstitutePending
Feb 6, 2019An open-label, multi-center extension study to investigate the efficacy and safety of cobomarsen (MRG-106) following systemic treatment, in subjects with ctcl,…Cobomarsen / Fludeoxyglucose 18FMiragen TherapeuticsPending
Aug 1, 2018Solar: a phase 2, randomized, open-label, parallel-group, active comparator, multi-center study to investigate the efficacy and safety of cobomarsen (MRG-106)…CobomarsenMiragen TherapeuticsOngoing

FDA orphan designations

Approved first, then open designations, newest first; 15 of 25
Aug 7, 2024LymphirTreatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic…Citius Oncology, Inc.Approved
Aug 8, 2018PoteligeoPOTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after…Kyowa Kirin Pharmaceutical Development Inc.Approved
Aug 23, 2013ValchlorTopical treatment of Stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed…Helsinn Birex Pharmaceuticals Ltd.Approved
Nov 5, 2009IstodaxTreatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapyCelgene CorporationApproved
Oct 6, 2006ZolinzaTreatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistant or recurrent…Merck & Co., Inc.Approved
Dec 29, 1999TargretinTreatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.Eisai, Inc.Approved
Feb 5, 1999OntakTreatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2…Eisai, Inc.Approved
Sep 22, 2023Resminostat mesilateTreatment of Cutaneous T-Cell Lymphoma (CTCL)4SC AGDesignated
Sep 14, 2022A ligand binding moiety to STAT3, a chemical linker, and a…Treatment of Cutaneous T-Cell Lymphoma (CTCL)Kymera TherapeuticsDesignated
Apr 4, 2018TenalisibTreatment of Cutaneous T-Cell LymphomaRhizen Pharmaceuticals SADesignated
Dec 19, 2017FenretinideTreatment of cutaneous T-cell lymphomaSciTech Development, LLCDesignated
Jun 14, 2017LacutamabTreatment of cutaneous T-cell lymphoma.Innate PharmaDesignated
May 24, 2017ResiquimodTreatment of cutaneous T-cell lymphomaGalderma Research and Development, LLCDesignated
Feb 6, 2017Brentuximab vedotinTreatment of cutaneous T-cell lymphomaSeagen Inc.Designated
Oct 12, 2016Liposomal vinorelbineTreatment of cutaneous t-cell lymphoma (CTCL)Taiwan Liposome Company, Ltd.Designated

Medicines authorised in the EU

Newest first
Mar 3, 2017LedagaChlormethine · orphanHelsinn Birex Pharmaceuticals Ltd.EMA ↗
Mar 29, 2001TargretinBexaroteneH.A.C. PharmaEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.